How did you become a scientist?
I always had a great interest in math and science as a child and teen (but also loved poetry, music, and reading). I wasn't sure of which direction to go, but in high school I really liked chemistry and physics and "floated" into chemical engineering at Columbia University and then biomedical engineering at Washington University, St. Louis. Studying chemical reactions and processes related to human health were interesting, but I was very inquisitive about understanding the cellular and molecular mechanisms underlying various physical and chemical observations. I had strong training in chemistry throughout my undergraduate years and master's degree, and going onto a PhD in biochemistry (protein chemistry) was a thrill! I studied the disulfide bonds of the gonadotropin hormones and thyroid-stimulating hormone (TSH) and the structure and functions of their subunits using biochemical and spectroscopic approaches.
When did you first become interested in reproductive biology and why?
During my PhD, I took courses in biochemistry, reproductive biology, and genetics which were necessary for understanding my thesis research and also very interesting and educational. Reproduction is a fascinating and complex field and so exciting to study! What led you to become a physician scientist rather than pursue a career in private practice?
I had an "ahaa" moment about going into medicine during my postdoctoral fellowship at the NIH. I was studying mRNA biosynthesis and processing of TSH subunits (after a postdoc at Rockefeller University with Gunter Blobel) and was in the Clinical Endocrinology Branch at NIDDK/NIH. A clinical fellow colleague invited me to go "on rounds" with the team, and that did it-I fell in love with the physician-patient relationship and that what we were studying in the lab was relevant for advancing human health. Rather than going to a faculty position to do research and teaching, I decided to go to medical school-intent on becoming an internist/endocrinologist. At Stanford University Medical School, I was able to continue to conduct research (on nerve growth factor), and after an internship in internal medicine, decided that reproductive endocrinology (after an obstetrics and gynecology residency) was the career path for me-clinically and in research. I had not considered going into private practice, as my research background propelled me to academic medicine. However, when my first NIH grant application and its revision did not score well, I did consider (briefly) going into private practice. My husband, Sakis Theologis, PhD, a plant biologist, commented that the system had invested too much in me to abandon ship. Indeed, I tried one more time, and when my NIH "FIRST" grant was awarded, I was sure I was on the right path.
Who were past scientists and mentors who inspired your research and influenced your career path?
I have been so fortunate throughout my career to have had superb mentors, an experience that has greatly strengthened my own commitment as a mentor. My PhD advisor, John Pierce, PhD, was a protein chemist, a scholar, a gentleman, and a superb mentor. Jesse Roth, MD, Bruce Weintroub, MD, and Irwin Chaiken, PhD, at the NIH were also great mentors, as was Eric Shooter, PhD, at Stanford. Ron Rosenfeld, MD, a pediatric endocrinologist at Stanford, had a major influence on my career through his mentorship, collaboration, and friendship-the latter of which endures today.
Looking back, what are the one or two decisions you made during your career that had the most impact?
Pursuing rigorous training in basic science and going to medical school and subsequent medical training.
What is the most important scientific accomplishment that you think you have made so far?
Discovery of IGFBP proteases: The early part of my research career as a faculty member at Stanford focused on insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and their roles in the female reproductive tract and human pregnancy. Our discovery, in collaboration with Ron Rosenfeld's group at Stanford, of a protease in human pregnancy serum that specifically cleaved IGFBP-3 and increased the bioavailabilty of IGF-I and IGF-II revealed a new and important member of the IGF family and a new mechanism of regulation of IGF action. This discovery opened the field to discoveries of other IGFBPs that had to be taken into account when interpreting the actions of these growth factors in pregnancy, reproduction more broadly, cancer, neuroscience, and other areas.
Transciptome of human endometrium: early in the functional genomics era, our lab was one of the first to perform genome-wide transcriptomics on human endometrial tissue across the menstrual cycle. We demonstrated distinct gene expression profiles characteristic of proliferative, early secretory, mid-secretory, and late secretory phases. Studying the transcriptome in women with endometriosis led to development of classifiers to diagnose and stage endometriosis from an endometrial sample compared to the gold standard of surgical diagnosis and staging. Obtaining, processing, and storing human tissue requires strict standard operating procedures (SOPs) which we developed for endometrial research in 2011 and also specifically for endometriosis research as a member of the World Endometriosis Research Foundation Phenome and Harmonization Project group in 2014.
Discovery of progesterone resistance in endometrial stromal fibroblasts (eSF) of women with endometriosis (and other inflammatory disorders) and that this is inherited from its progenitor, the endometrial mesenchymal stem cell, a pericyte. As the response of eSF to progesterone is essential for embryo implantation, identifying that the abnormality is upstream in the endometrial mesenchymal stem cell opens the door to understanding causes (e.g. inflammation, lifestyle/environment) and mechanisms (e.g. epigenetic, other) with the promise of targeted therapies and/or lifestyle/environmental changes to improve pregnancy outcomes in women with endometriosis and other inflammatory disorders. This is a current area of focus of our lab today.
What has been your philosophy in training and mentoring young physicians and scientists?
Get the best training you can, have a few projects since not everything always pans out, go the extra mile, replicate replicate replicate, focus focus focus, aim to publish in high-impact journals, collaborate to expand one's horizons, keep current in reading the literature not only in reproductive biology and medicine but in other fields as well (genetics, genomics, imaging, quantitative approaches, etc), and persevere.
What do you consider the greatest breakthroughs in the field of reproductive medicine and why? r Discovery of the hypothalamic peptides, hormones, and genetics that govern the hypothalamic-pituitary-gonadal axis (HP)-gonadal axis and function, and development of radioimmunoassays of hormones have advanced diagnosis of reproductive compromise and advanced therapies for hypogonadism and infertility in women and men.
r Development of mouse models using genetic approaches to discover genes important in gonadal development and function and infertility has been a major contribution to reproductive science. This is still an evolving field in translating this to reproductive medicine and is likely the next "frontier" in fertility evaluation, treatments, response to therapies, and prognostics in this space.
r In vitro fertilization has revolutionized infertility therapy, enabled human gamete and embryo research, enabled human embryonic stem cell research, and has enabled pre-implantation genetic testing.
r Discovery that the placenta does not protect the fetus from toxic insults, and the ongoing research on the complexities of immune tolerance during gestation-all important to enhance the health of the next and subsequent generations.
r Discovery that surgery on a developing fetus does not result in scarring-a major advance for fetal surgery to correct various abnormalities in utero and as a model for wound healing more broadly.
What do you see as the biggest challenges for young researchers entering the field of reproductive biology today? r Because of the major advances in genomics, genetics, and technology more broadly, it is a challenge to master the fundamentals for successful investigation. For example, having sufficient mathematical and informatics training to be able to write code and interpret one's own data and be able to "speak the language" of informatics colleagues is a challenge but is important.
r If one is interested in translational science, it can be a challenge to understand the clinical implications, and finding clinical colleagues with whom to interact and collaborate can be a challenge.
r Funding is a major challenge, and the whole field of reproductive biology research is in jeopardy. Having mentors who can provide Downloaded from https://academic.oup.com/biolreprod/article-abstract/98/4/437/4828315 by OUP site access user on 08 October 2018 guidance for options and opportunities is key as is keeping the flame alive.
Would you enter this career again?
Definitely. I love what I do in clinical care, teaching, and translational research. I have been very fortunate to have had so many talented trainees, superb mentors, and collaborators and support along the way, and to have been in a position to mentor the next generation, contribute to translational medicine, the well-being of my patients, and work as a citizen in our national research and educational organizations on behalf of advancing reproductive science and reproductive medicine.
Romana A. Nowak
Department of Animal Sciences, University of Illinois, Urbana-Champaign, Illinois
